Skip to main navigation

Company
Pathologies
Product Candidates
Newsroom
- News
- Presentations
- Publications
- Links
Investors

Breadcrumb

Home / Investors / Press Releases /

Press Releases

Keyword Search

Year

Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo

07/29/20

Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study

05/26/20

Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results

04/16/20

Auris Medical Provides Update on Intranasal Betahistine Development Program

04/03/20

Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine

03/05/20

Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model

02/25/20

Auris Medical Announces Notice of Allowance for European Patent Application

01/10/20

Investors

Investors

Investor Relations
Events and Presentations
Corporate Governance
Financial Information
Press Releases
Stock Information
Major Shareholders
Investor FAQs
Investor Contact
Information Request
Email Alerts
Information related to Reverse Split

Investor Toolkit

Print Page
RSS Feeds

Careers | Contacts

Copyright © Auris Medical 2020